BARDINA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 1.866
EU - Europa 1.101
AS - Asia 358
AF - Africa 39
SA - Sud America 21
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 3.403
Nazione #
US - Stati Uniti d'America 1.846
IT - Italia 233
CN - Cina 188
DE - Germania 173
SE - Svezia 135
IE - Irlanda 127
UA - Ucraina 81
FR - Francia 73
DK - Danimarca 57
FI - Finlandia 53
VN - Vietnam 49
GB - Regno Unito 45
SN - Senegal 32
IN - India 26
KR - Corea 23
GR - Grecia 21
PL - Polonia 20
BE - Belgio 17
ES - Italia 17
CA - Canada 16
TR - Turchia 14
IR - Iran 12
JP - Giappone 12
SG - Singapore 12
AT - Austria 11
NL - Olanda 11
IL - Israele 10
BR - Brasile 9
EU - Europa 7
NZ - Nuova Zelanda 7
CO - Colombia 6
NO - Norvegia 6
MU - Mauritius 4
MX - Messico 4
RO - Romania 4
RU - Federazione Russa 4
UZ - Uzbekistan 4
AU - Australia 3
CZ - Repubblica Ceca 3
HK - Hong Kong 3
BG - Bulgaria 2
CH - Svizzera 2
EC - Ecuador 2
ID - Indonesia 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AR - Argentina 1
CL - Cile 1
DZ - Algeria 1
HR - Croazia 1
HU - Ungheria 1
LB - Libano 1
MD - Moldavia 1
MK - Macedonia 1
NP - Nepal 1
PK - Pakistan 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.403
Città #
Chandler 319
Ann Arbor 192
Fremont 140
Beijing 131
Dublin 123
Fairfield 92
Torino 81
Ashburn 77
Houston 62
Wilmington 55
Dearborn 53
Nyköping 52
Woodbridge 50
Dong Ket 47
Medford 42
Villeurbanne 42
Jacksonville 40
Redwood City 37
Princeton 36
Seattle 34
Cambridge 30
Turin 25
Pisa 20
Milan 18
Warsaw 18
New York 17
Washington 15
Boardman 11
Brussels 11
Vienna 11
Guangzhou 10
San Diego 10
Boston 9
Toronto 9
Hangzhou 8
Mountain View 8
Düsseldorf 7
Menlo Park 7
Nanjing 7
Norwalk 7
Rome 7
Coventry 6
Duncan 6
Kunming 6
Dallas 5
Hefei 5
Helsinki 5
Kozani 5
Stavanger 5
Tokyo 5
Heidelberg 4
Kharkiv 4
Leawood 4
Madrid 4
Netanya 4
Oldenburg 4
Paris 4
Amsterdam 3
Cankaya 3
Cork 3
Curitiba 3
Gazi 3
Hamilton 3
Istanbul 3
Jinan 3
Nürnberg 3
Palermo 3
Pamplona 3
Salt Lake City 3
San Mateo 3
Sevilla 3
Singapore 3
Auckland 2
Bologna 2
Central District 2
Coimbatore 2
Frankfurt am Main 2
Glen Mills 2
Guayaquil 2
Hasselt 2
Hebei 2
Jerusalem 2
Johannesburg 2
Leiden 2
London 2
Magelang 2
Montevideo 2
Montreal 2
Munich 2
Naples 2
Neu-Ulm 2
Niagara Falls 2
Philadelphia 2
Phoenix 2
Portland 2
Prague 2
Redmond 2
Saluzzo 2
Siegen 2
Southend 2
Totale 2.147
Nome #
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 371
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 287
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 176
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 165
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 144
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 142
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 140
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 134
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 131
Natalizumab in Multiple Sclerosis: Long-Term Management 128
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 111
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT 91
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 91
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 87
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 83
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 82
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 79
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 75
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 75
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity 75
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 74
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 71
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy 71
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 68
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 64
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  62
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 61
T helper 22 increase in multiple sclerosis patints: phenotypical and functional characterization 56
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 54
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 43
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients 41
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 40
Role of Th22 expansion in multiple sclerosis disease activity 38
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis 37
Totale 3.528
Categoria #
all - tutte 8.371
article - articoli 0
book - libri 0
conference - conferenze 5.009
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.380


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201996 0 0 0 0 0 0 0 0 0 31 34 31
2019/2020471 14 18 27 53 23 82 48 36 38 63 34 35
2020/2021573 41 41 18 85 50 46 49 27 57 37 55 67
2021/2022571 18 19 19 34 36 42 31 40 25 84 120 103
2022/2023809 63 70 27 101 74 182 44 65 95 28 42 18
2023/2024282 50 48 23 23 30 49 9 33 0 17 0 0
Totale 3.528